Mar 10, 2026 (MarketLine via COMTEX) --
Cassava Sciences is rebranding as Filana Therapeutics, refocusing on developing therapies that modulate filamin A to treat central nervous system disorders such as TSC-related epilepsy.
Cassava Sciences, Inc. (NASDAQ: SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.
The Company will begin trading under the new ticker symbol "FLNA" on the Nasdaq Capital Market at the open of the market on March 11, 2026.
"The launch of Filana Therapeutics represents a new beginning for our Company. Growing evidence suggests that filamin A is an important regulator of neuronal development and that modulating filamin A may provide a new approach to treating CNS disorders such as TSC-related epilepsy. Centering our identity on filamin A reflects our dedication to rigorous scientific discovery and to bringing new treatment options to patients and their families," said Rick Barry, President and Chief Executive Officer of Filana Therapeutics.
The updated corporate website is available at: https://www.filanatx.com.
About TSC and TSC-related Epilepsy
TSC is a rare genetic disorder resulting from a mutation in the TSC1 or TSC2 gene. This affects the mechanistic target of rapamycin (mTOR) pathway and can cause tumors to grow in multiple organs. Epilepsy is the most common health issue affecting the TSC community, with 80% to 90% of TSC patients experiencing seizures. TSC-related epilepsy affects approximately 45,000 people in the U.S. Most patients start having seizures within their first year of life. Even with multiple approved treatments, more than 60% of TSC patients remain refractory to antiepileptic therapy.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_478962808/2227/2026-05-11T22:42:22
Copyright (C) 2026 Datamonitor. All rights reserved
